CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest

T Bertero1, C Gastaldi, I Bourget-Ponzio

  • 1CNRS UMR 7275, IPMC, Physiological Genomics of the Eukaryotes, Valbonne, France.

Insights

MicroRNA-483-3p accumulation signals keratinocyte cell cycle exit during wound healing. This microRNA targets CDC25A phosphatase, halting cell proliferation and differentiation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Dermatology

Background:

  • Cell cycle regulation is crucial for tissue repair after injury.
  • While cell cycle entry is understood, cell cycle exit mechanisms remain unclear.
  • Keratinocyte proliferation and differentiation are key to wound healing.

Purpose of the Study:

  • To identify the molecular mechanisms regulating keratinocyte cell cycle exit during wound closure.
  • To investigate the role of microRNA-483-3p in controlling cell cycle arrest.
  • To elucidate the downstream targets and signaling pathways affected by miR-483-3p.

Main Methods:

  • Utilized mechanical injury and serum addition models for cell cycle synchronization.
  • Quantified miR-483-3p accumulation during wound closure.
  • Employed anti-miRNA and protector molecules to block miR-483-3p activity.
  • Analyzed targeting of CDC25A phosphatase and its impact on CDK4/6 and cyclin D/E interactions.

Main Results:

  • miR-483-3p significantly accumulates during the final stages of wound closure, inducing cell cycle arrest.
  • Blocking miR-483-3p delays cell cycle exit and retards keratinocyte differentiation.
  • miR-483-3p directly targets CDC25A phosphatase, leading to G1 phase arrest.
  • Silencing of CDC25A by miR-483-3p results in increased tyrosine phosphorylation of CDK4/6, inhibiting their activation.

Conclusions:

  • miR-483-3p is a critical regulator of keratinocyte cell cycle exit and differentiation during wound healing.
  • The miR-483-3p/CDC25A/CDK4/6 pathway represents a novel mechanism for controlling cell proliferation.
  • This finding offers potential therapeutic targets for enhancing wound repair and managing proliferative disorders.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.